FDC Share News - Latest Updates, Live News & More

Latest news about FDC

FDC Q3 Results: Revenue Dips to ₹4.6B While Net Profit Grows 12% 2 hrs ago Today

FDC's Q3 results show mixed performance with revenue declining marginally to ₹4.6 billion from ₹4.64 billion year-over-year, while profitability metrics remained strong with net profit growing 11.72% to ₹572 million and EBITDA rising 12% to ₹523 million, accompanied by significant margin expansion of 125 basis points.

FDC Limited Declares Interim Dividend of Rs 5 Per Share Following Board Meeting 5 days ago

FDC Limited Shareholders Approve Registered Office Relocation from Waluj to Mumbai 8 days ago

FDC Limited Receives USFDA Approval for Fluconazole Tablets Across Multiple Dosage Strengths Jan 09, 2026

FDC Limited Receives US FDA Approval for Fluconazole Tablets in Multiple Strengths Jan 09, 2026

More news about FDC

29Dec 25

FDC Limited Receives ₹15.61 Crore GST Demand Notice from Maharashtra State Tax Department

FDC Limited has received a GST demand notice of ₹15.61 crores from the Maharashtra State Tax Department for alleged tax misclassification in FY 2021-22. The demand includes ₹8.42 crores in differential tax, ₹6.35 crores in interest, and ₹0.84 crores in penalties. The company allegedly charged 18% GST instead of the applicable 28% rate on certain products. FDC Limited is reviewing the order and plans to pursue legal remedies, stating it doesn't expect any material financial impact.

19Dec 25

FDC Limited Board Approves Registered Office Relocation to Mumbai

FDC Limited's Board of Directors approved relocating the company's registered office from Waluj, Chhatrapati Sambhajinagar to Mumbai on December 19, 2025. The move requires member approval through postal ballot, with e-voting scheduled from December 30, 2025 to January 28, 2026, and results expected by January 29, 2026.

05Nov 25

FDC Limited Reports Mixed Q2 Results: Revenue Dips, Profit Declines Amid Market Challenges

FDC Limited's Q2 FY2026 results show a decline in both revenue and profitability. Standalone revenue decreased by 5.61% to ₹102,508.02 lakhs, while consolidated revenue fell by 5.54% to ₹103,773.60 lakhs. Standalone PAT declined by 31.71% to ₹12,571.32 lakhs, and consolidated PAT dropped by 32.60% to ₹12,584.17 lakhs. However, half-yearly results showed some resilience with standalone revenue increasing by 6.38% and PAT by 4.78%. The company recognized a fair value loss of ₹143.36 lakhs in Q2 but a net fair value gain of ₹1,905.36 lakhs for H1. Earnings per share for Q2 FY2026 stood at ₹7.72, down from ₹11.30 in Q2 FY2025.

17Oct 25

FDC Limited Announces CFO Transition: Vijay Bhatt Resigns, Vishal Shah Appointed

FDC Limited's Board of Directors has accepted the resignation of Vijay Dharmadatt Bhatt as CFO and KMP, effective October 20, 2025. Vishal Shah, with 20 years of experience in pharmaceutical finance, will take over as the new CFO and KMP from October 24, 2025. Bhatt cited pursuit of better prospects for his departure. Shah's appointment was based on recommendations from the Nomination and Remuneration Committee and the Audit Committee.

04Oct 25

FDC Ltd Secures U.S. FDA Approval for Pilocarpine Hydrochloride Eye Drops

FDC Ltd has received U.S. FDA approval for Pilocarpine Hydrochloride Ophthalmic Solution USP in 1%, 2%, and 4% concentrations, each in 15 mL packages. This approval allows the company to market these eye drops in the United States, potentially opening new revenue streams. FDC Ltd has informed the BSE Limited and National Stock Exchange of India Ltd about this development in compliance with SEBI regulations.

06Sept 25

FDC Limited Reports Q1 FY21 Results: Revenue Dips, Profits Surge Amid Pandemic

FDC Limited's Q1 FY21 results show resilience amid COVID-19 challenges. Operating revenue decreased by 10.29% to ₹308.18 crore, but profitability improved significantly. EBITDA increased by 49.05% to ₹131.55 crore, while Profit After Tax grew by 63.14% to ₹91.72 crore. Earnings Per Share rose by 66.46% to ₹5.36. Domestic sales declined by 13.66%, export formulations fell slightly by 3.01%, but export API grew by 36.36%. The company plans to launch Favipiravir in India for COVID-19 treatment and introduce Olopatadine ophthalmic solution in the US market.

05Sept 25

FDC Limited Reports Strong Q1 Results, Approves Share Buyback and Director Reappointments

FDC Limited reported robust Q1 FY2024 results with revenue of Rs. 53,003.98 lakhs and net profit of Rs. 10,855.13 lakhs. The company approved a share buyback of 31 lakh equity shares at Rs. 500 per share, totaling Rs. 155 crores. The board reappointed three key directors for five-year terms. FDC also approved acquisition of an additional 7% stake in its subsidiary, Fair Deal Corporation Pharmaceutical SA, making it a wholly-owned entity.

07Aug 25

FDC Limited Reports Robust Q1 Performance with 33% Profit Growth

FDC Limited announced impressive Q1 financial results, with consolidated revenue reaching Rs. 648.41 crore and net profit at Rs. 121.35 crore. The company saw a 2.9% increase in standalone revenue and a 33% rise in consolidated net profit compared to the same quarter last year. The Board also approved the reappointment of Mr. Ashok A. Chandavarkar as Executive Director for a five-year term starting March 1, 2026, subject to shareholder approval.

07Aug 25

FDC Reports Steady Q1 Performance with Marginal Revenue Growth

FDC Limited's Q1 financial results show a steady performance. The company maintained a consolidated net profit of ₹120.00 crore, identical to last year's Q1. Revenue slightly increased to ₹650.00 crore from ₹640.00 crore, marking a 1.56% year-over-year growth. However, EBITDA decreased to ₹140.00 crore from ₹146.00 crore, with the EBITDA margin compressing to 21.54% from 22.81% year-over-year.

28May 25

FDC Reports Mixed Q4 Results: Revenue Up, Profit Down

FDC Limited's Q4 financial results show a 6.49% year-over-year revenue increase to ₹4.92 billion. However, profitability declined with EBITDA falling 4.12% to ₹539.80 crore and net profit decreasing 16.48% to ₹386.70 crore. The EBITDA margin compressed to 10.97% from 12.19% in the previous year.

30Apr 25

FDC Limited Approves Rs 140 Crore Expansion of Liquid Oral Facility at Sinnar Plant

FDC Limited has approved a Rs 140 crore expansion plan for its liquid oral facility at the Sinnar plant. The project will add 77,000 KL per annum to production capacity, to be completed in 18-24 months. Funded through internal accruals, this expansion aims to meet high capacity utilization (70-80%) and growing market demand. The investment is expected to strengthen FDC's manufacturing infrastructure and market position in the pharmaceutical sector.